Future LRMN Events

LRMN & Miltenyi Biotec

Cancer immunotherapy using T cells was recently named 'Breakthrough of the Year' on the front cover of Science Magazine. Our March 2015 LRMN event brings you two of the leading players championing the field of CAR-T therapy: UPenn, who have joined forces with Novartis, and Juno Therapeutics.

This meeting is kindly supported by Miltenyi Biotec and is FREE OF CHARGE to attend. Miltenyi Biotec provides cutting-edge, integrated products in sample preparation, cell isolation, cell sorting, flow cytometry and cell culture that advance biomedical research and cellular therapy. In particular, Miltenyi have a long and unique experience in GMP cell processing, providing tools and full workflow solutions for ATMP manufacture. The CliniMACS Prodigy platform, along with a wide portfolio of GMP Raw Materials (media, cytokines, stimulation reagents, etc), facilitate closed-system processing, automation, and feasible outscaling of various ATMP's, such as CAR/TCR T Cells. Today, Miltenyi Biotec has more than 1,400 employees in 22 countries, all dedicated to empowering discovery and impacting lives.

The meeting will take place on Tuesday 31st March 2015 at 6.00 pm in the Gustave Tuck Lecture Theatre, Wilkins Building, University College London – a short walk from Euston Square, Goodge Street and Warren Street Tube Stations and Euston Station.

Registration: 6.00 - 6.30 pm
Presentations: 6.30 - 8.10 pm
Networking Reception 8.10 - 10.00 pm



18.00 - Registration over tea and coffee in the Gustave Tuck Lecture Theatre (Wilkins Building, UCL)

18.30 - Welcome - Dr. Emily Culme-Seymour, LRMN (London, UK) and Jason Jones, Miltenyi Biotec (UK)

18.35 - "Engineering Targeted Immunity from Patient's Own Cells to Treat Untreatable Cancers" - Professor Bruce Levine, Abramson Cancer Centre of the University of Pennsylvania (Philadelphia, PA, US)

19.15 - Q & A

19.20 - "Juno's Approach to Cellular Immunotherapy" - Hans Bishop, CEO & President, Juno Therapeutics (Seattle, WA, US)

20.00 - Q & A

20.05 - Closing remarks - Prof. Chris Mason, Advanced Centre for Biochemical Engineering, UCL (London, UK) and Jason Jones, Miltenyi Biotec (UK)

20.10 - 22.00 - LRMN Reception - Network whilst enjoying a glass of wine or two in the Haldane Room (Wilkins Building, UCL)



Miltenyi Biotec

Regenerative Medicine'


PLEASE NOTE THAT DUE TO LECTURE THEATRE SEATING CAPACITY, IF YOU WISH TO ATTEND THIS EVENT YOU MUST REGISTER, OTHERWISE UNFORTUNATELY YOU WILL NOT BE ABLE TO GAIN ADMISSION. Seat allocation is on a first come, first served basis. If you wish to attend, all that is required is to email office@lrmn.com and type 'I will attend' in the subject box. Please only register if you can definitely make the meeting. If you have to cancel later do please let us know.

The LRMN Team very much look forward to welcoming you at 6.00 pm on Tuesday 31st March 2015 for an event that will focus on the very latest in the field of T cell immunotherapies.


LRMN & Cell Therapy Catapult

The LRMN is working together again with the Cell Therapy Catapult to hold another event in Spring 2015.

The Cell Therapy Catapult was established in 2012 as a centre of excellence in innovation, with the core purpose of building a world-leading cell therapy industry in the UK. Supported by Innovate UK (formerly the Technology Strategy Board), it's mission is to drive the growth of the industry by helping cell therapy organisations across the world translate early stage research into commercially viable and investable therapies. Based in London at Guy's Hospital, the centre focusses on collaboration and lowering barriers to investment and funding.

More information on
this event, including a finalised date and the programme will be given in due course, with invitations sent out to the LRMN mailing list as usual.


LRMN & GE Healthcare

The LRMN is working together with GE Healthcare Life Sciences to hold an event in late Spring 2015.

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Their expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.

More information on
this event, including a finalised date and the programme will be given in due course, with invitations sent out to the LRMN mailing list as usual.